- Home
- KAVL vs APVO Comparison
KAVL vs APVO Comparison
Compare KAVL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- APVO
- Stock Information
- Founded
- KAVL 1998
- APVO 2016
- Country
- KAVL United States
- APVO United States
- Employees
- KAVL N/A
- APVO N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- APVO Health Care
- Exchange
- KAVL Nasdaq
- APVO Nasdaq
- Market Cap
- KAVL 7.9M
- APVO 4.1M
- IPO Year
- KAVL N/A
- APVO N/A
- Fundamental
- Price
- KAVL $0.48
- APVO $2.96
- Analyst Decision
- KAVL
- APVO Strong Buy
- Analyst Count
- KAVL 0
- APVO 1
- Target Price
- KAVL N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- KAVL 33.1K
- APVO 6.7M
- Earning Date
- KAVL 07-15-2025
- APVO 08-07-2025
- Dividend Yield
- KAVL N/A
- APVO N/A
- EPS Growth
- KAVL N/A
- APVO N/A
- EPS
- KAVL N/A
- APVO N/A
- Revenue
- KAVL $1,698,426.00
- APVO N/A
- Revenue This Year
- KAVL N/A
- APVO N/A
- Revenue Next Year
- KAVL N/A
- APVO N/A
- P/E Ratio
- KAVL N/A
- APVO N/A
- Revenue Growth
- KAVL N/A
- APVO N/A
- 52 Week Low
- KAVL $0.45
- APVO $2.81
- 52 Week High
- KAVL $1.95
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- KAVL 32.59
- APVO 33.90
- Support Level
- KAVL $0.45
- APVO $2.92
- Resistance Level
- KAVL $0.54
- APVO $3.19
- Average True Range (ATR)
- KAVL 0.04
- APVO 1.05
- MACD
- KAVL -0.01
- APVO 0.24
- Stochastic Oscillator
- KAVL 19.23
- APVO 2.23
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.